Pharmacological inhibition of RPS6KA1 increased sensitivity to venetoclax/azacitidine in parental AML cells and could restore sensitivity of venetoclax/azacitidine-resistant AML. The gene discussed is RPS6KA1; the disease is acute myeloid leukemia.